Intralesional Verapamil Prevents the Progression of Peyronie's Disease

Urology

Volumn 69, Issue 6, 2007, Pages 1181-1184

  Bennett, Nelson E ^a,b   Guhring, Patricia ^a   Mulhall, John P ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VERAPAMIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFORMITY; DRUG EFFICACY; ECCHYMOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM FUNCTION; MORPHOLOGY; PAIN; PEYRONIE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PENILE INDURATION; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; VERAPAMIL;

EID: 34250017423     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.02.042     Document Type: Article

References (19)

1. Benson G.S. Peyronie's disease. J Urol 149 (1993) 1326-1326
2. Mulhall J.P., Anderson M.S., Lubrano T., et al. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 14 (2002) 397-405
3. Brock G., Hsu G.L., Nunes L., et al. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 157 (1997) 276-281
4. Levine L.A. Advances in the medical therapy of Peyronie's disease: a brief review. Int J Impot Res 10 (1998) 123-124
5. Schwarzer U., Sommer F., Klotz T., et al. The prevalence of Peyronie's disease: results of a large survey. BJU Int 88 (2001) 727-730
6. Mulhall J.P., Creech S.D., Boorjian S.A., et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 171 (2004) 2350-2353
7. Williams J.L., and Thomas G.G. The natural history of Peyronie's disease. J Urol 103 (1970) 75-76
8. Gelbard M.K., Dorey F., and James K. The natural history of Peyronie's disease. J Urol 144 (1990) 1376-1379
9. Kadioglu A., Tefekli A., Erol B., et al. A retrospective review of 307 men with Peyronie's disease. J Urol 168 (2002) 1075-1079
10. Gelbard M.K., James K., Riach P., et al. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 149 (1993) 56-58
11. Anderson M.S., Shankey T.V., Lubrano T., et al. Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 12 suppl 3 (2000) S25-S31
12. Russell B. Treatment of lupus vulgaris by intralesional injections of calciferol: its use in localized, recurrent, or refractory cases. AMA Arch Derm Syphilol 64 (1951) 676-683
13. Saray Y., and Gulec A.T. Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. Int J Dermatol 44 (2005) 777-784
14. Teasley G.H. Peyronie's disease: a new approach. J Urol 71 (1954) 611-614
15. Bodner H., Howard A.H., and Kaplan J.H. Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol 72 (1954) 400-403
16. Lee R.C., Doong H., and Jellema A.F. The response of burn scars to intralesional verapamil. Report of five cases. Arch Surg 129 (1994) 107-111
17. Levine L.A., Merrick P.F., and Lee R.C. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 151 (1994) 1522-1524
18. Levine L.A., Goldman K.E., and Greenfield J.M. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 168 (2002) 621-626
19. Mulhall J.P., Schiff J., and Guhring P. Analysis of the natural history of Peyronie's disease. J Urol 175 (2006) 2115-2118